In addition, the combination of VEGF blockers (e.g., bevacizumab or ramucirumab) with PD-1/PD-L1 ICIs has displayed the ability to remodel the immunosuppressive microenvironment characteristic of tumor growth. Here, VEGFA is linked to neoplasm.